Self-management for bronchiectasis. by Kelly, Carol et al.
Cochrane Database of Systematic Reviews
Self-management for bronchiectasis (Review)
Kelly C, Grundy S, Lynes D, Evans DJW, Gudur S, Milan SJ, Spencer S
Kelly C, Grundy S, Lynes D, Evans DJW, Gudur S, Milan SJ, Spencer S.
Self-management for bronchiectasis.
Cochrane Database of Systematic Reviews 2018, Issue 2. Art. No.: CD012528.
DOI: 10.1002/14651858.CD012528.pub2.
www.cochranelibrary.com
Self-management for bronchiectasis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
7BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
13RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
Figure 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
18DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
20AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
20ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
21REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
25CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
33DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 Early rehab versus usual care, Outcome 1 SGRQ Total: mean difference. . . . . . . 35
Analysis 1.2. Comparison 1 Early rehab versus usual care, Outcome 2 FEV1 L: mean difference. . . . . . . . 36
Analysis 1.3. Comparison 1 Early rehab versus usual care, Outcome 3 Mortality. . . . . . . . . . . . . . 37
Analysis 2.1. Comparison 2 Expert patient programme versus usual care, Outcome 1 SGRQ Total: mean difference. 38
Analysis 2.2. Comparison 2 Expert patient programme versus usual care, Outcome 2 Self-efficacy: Exercise. . . . 39
Analysis 2.3. Comparison 2 Expert patient programme versus usual care, Outcome 3 Self-efficacy: Disease info. . . 40
Analysis 2.4. Comparison 2 Expert patient programme versus usual care, Outcome 4 Self-efficacy: Obtain help. . . 41
Analysis 2.5. Comparison 2 Expert patient programme versus usual care, Outcome 5 Self-efficacy: Communication. 42
Analysis 2.6. Comparison 2 Expert patient programme versus usual care, Outcome 6 Self-efficacy: Manage disease. . 43
Analysis 2.7. Comparison 2 Expert patient programme versus usual care, Outcome 7 Self-efficacy: Do chores. . . . 44
Analysis 2.8. Comparison 2 Expert patient programme versus usual care, Outcome 8 Self-efficacy: Social activity. . . 45
Analysis 2.9. Comparison 2 Expert patient programme versus usual care, Outcome 9 Self-efficacy: Manage symptoms. 46
Analysis 2.10. Comparison 2 Expert patient programme versus usual care, Outcome 10 Self-efficacy: Manage
breathlessness. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
Analysis 2.11. Comparison 2 Expert patient programme versus usual care, Outcome 11 Self-efficacy: Manage depression. 48
48APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
50CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
51DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
51SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iSelf-management for bronchiectasis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Self-management for bronchiectasis
Carol Kelly1, Seamus Grundy2,3, Dave Lynes1, David JW Evans4, Sharada Gudur5 , Stephen J Milan6, Sally Spencer7
1Faculty of Health and Social Care, Edge Hill University, Ormskirk, UK. 2Department of Thoracic Medicine, Aintree University
Hospital, Liverpool,UK. 3Institute ofTranslationalMedicine,University of Liverpool, Liverpool,UK. 4LancasterHealthHub, Lancaster
University, Lancaster, UK. 5Department of Respiratory Medicine, Lancashire Teaching Hospitals NHS Foundation Trust, Preston,
UK. 6Medical School, Lancaster University, Lancaster, UK. 7Postgraduate Medical Institute, Edge Hill University, Ormskirk, UK
Contact address: Sally Spencer, Postgraduate Medical Institute, Edge Hill University, St Helens Road, Ormskirk, Lancashire, L39 4QP,
UK. spencesa@edgehill.ac.uk.
Editorial group: Cochrane Airways Group.
Publication status and date: New, published in Issue 2, 2018.
Citation: Kelly C, Grundy S, Lynes D, Evans DJW, Gudur S, Milan SJ, Spencer S. Self-management for bronchiectasis. Cochrane
Database of Systematic Reviews 2018, Issue 2. Art. No.: CD012528. DOI: 10.1002/14651858.CD012528.pub2.
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Bronchiectasis is a long term respiratory condition with an increasing rate of diagnosis. It is associated with persistent symptoms,
repeated infective exacerbations, and reduced quality of life, imposing a burden on individuals and healthcare systems. The main aims
of therapeutic management are to reduce exacerbations and improve quality of life. Self-management interventions are potentially
important for empowering people with bronchiectasis to manage their condition more effectively and to seek care in a timely manner.
Self-management interventions are beneficial in the management of other airways diseases such as asthma and COPD (chronic
obstructive pulmonary disease) and have been identified as a research priority for bronchiectasis.
Objectives
To assess the efficacy, cost-effectiveness and adverse effects of self-management interventions for adults and children with non-cystic
fibrosis bronchiectasis.
Search methods
We searched the Cochrane Airways Specialised Register of trials, clinical trials registers, reference lists of included studies and review
articles, and relevant manufacturers’ websites up to 13 December 2017.
Selection criteria
We included all randomised controlled trials of any duration that included adults or children with a diagnosis of non-cystic fibrosis
bronchiectasis assessing self-management interventions delivered in any form. Self-management interventions included at least two
of the following elements: patient education, airway clearance techniques, adherence to medication, exercise (including pulmonary
rehabilitation) and action plans.
Data collection and analysis
Two review authors independently screened searches, extracted study characteristics and outcome data and assessed risk of bias for each
included study. Primary outcomes were, health-related quality of life, exacerbation frequency and serious adverse events. Secondary
outcomes were the number of participants admitted to hospital on at least one occasion, lung function, symptoms, self-efficacy and
economic costs. We used a random effects model for analyses and standard Cochrane methods throughout.
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Main results
Two studies with a total of 84 participants were included: a 12-month RCT of early rehabilitation in adults of mean age 72 years
conducted in two centres in England (UK) and a six-month proof-of-concept RCT of an expert patient programme (EPP) in adults
of mean age 60 years in a single regional respiratory centre in Northern Ireland (UK). The EPP was delivered in group format once a
week for eight weeks using standardised EPP materials plus disease-specific education including airway clearance techniques, dealing
with symptoms, exacerbations, health promotion and available support. We did not find any studies that included children. Data
aggregation was not possible and findings are reported narratively in the review.
For the primary outcomes, both studies reported health-related quality of life, as measured by the St George’s Respiratory Questionnaire
(SGRQ), but there was no clear evidence of benefit. In one study, the mean SGRQ total scores were not significantly different at 6
weeks’, 3 months’ and 12 months’ follow-up (12 months mean difference (MD) -10.27, 95% confidence interval (CI) -45.15 to 24.61).
In the second study there were no significant differences in SGRQ. Total scores were not significantly different between groups (six
months, MD 3.20, 95% CI -6.64 to 13.04). We judged the evidence for this outcome as low or very low. Neither of the included studies
reported data on exacerbations requiring antibiotics. For serious adverse events, one study reported more deaths in the intervention
group compared to the control group, (intervention: 4 of 8, control: 2 of 12), though interpretation is limited by the low event rate
and the small number of participants in each group.
For our secondary outcomes, there was no evidence of benefit in terms of frequency of hospital admissions or FEV1 L, based on very low-
quality evidence. One study reported self-efficacy using the Chronic Disease Self-Efficacy scale, which comprises 10 components. All
scales showed significant benefit from the intervention but effects were only sustained to study endpoint on the Managing Depression
scale. Further details are reported in the main review. Based on overall study quality, we judged this evidence as low quality. Neither
study reported data on respiratory symptoms, economic costs or adverse events.
Authors’ conclusions
There is insufficient evidence to determine whether self-management interventions benefit people with bronchiectasis. In the absence
of high-quality evidence it is advisable that practitioners adhere to current international guidelines that advocate self-management for
people with bronchiectasis.
Future studies should aim to clearly define and justify the specific nature of self-management, measure clinically important outcomes
and include children as well as adults.
P L A I N L A N G U A G E S U M M A R Y
Self-management for non-cystic fibrosis bronchiectasis
Background
Bronchiectasis is a respiratory condition that may occur in both children and adults and is being diagnosed with increasing frequency.
It is a long-term condition, where people have recurrent chest infections and symptoms that include cough, mucus production and
recurrent flare-ups (exacerbations) that reduce their quality of life. The main aims of management are to reduce the risk of flare-ups
using various treatments including antibiotics, inhalers and physiotherapy exercises. It is important for people/carers to stick to their
treatments and self-management strategies can help people to do this by teaching them about their condition, available treatments,
exercise and what to do if their condition changes. The objective of the review is to assess the effectiveness and value for money of self-
management interventions for adults and children with non-cystic fibrosis bronchiectasis.
Review question
We assessed the benefits and possible harms of self-management strategies, including patient education, airway clearance techniques,
education aimed at increasing adherence to medication, exercise (including pulmonary rehabilitation), and action plans for children
and adults with bronchiectasis.
Study characteristics
We conducted a search on 13 December 2017 and found just two UK studies that included 84 participants, comparing a self-
management approach with normal care for adults with bronchiectasis. One study looked at the impact of an expert patient self-
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management programme and the other, involving just a small number of participants with bronchiectasis, looked at self-management
in combination with exercises to improve lung function. Neither study included children.
Main results
Health-related quality of life did not improve in either study. Although there were more deaths in the group receiving self-management
in one study, the numbers were very small and we do not know whether the difference is meaningful. The number of admissions to
hospital, and lung function showed no benefit from self-management. In one of the studies, people receiving self-management felt more
empowered to manage their condition. There was no information on the impact of self-management on symptoms of bronchiectasis,
adverse events or potential cost savings arising from more effective self-management. There are no studies looking at self-management
in children.
Overall there is not enough information to assess whether strategies to support self-management may help people with bronchiectasis
and further studies are needed. Future studies will need to look at how often flare ups occur, how often antibiotics are prescribed, and
how long for, whether people have a better quality of life, and the impact of self-management on costs of care. It is also important to
look at self-management for bronchiectasis in children.
Quality of the results
This review is based on only two small trials and the quality of the studies is very poor. With only two studies looking at very specific
approaches to self-management we cannot say with any degree of certainty whether self-management strategies work for people with
bronchiectasis, but until further evidence is available we advocate adherence to current international guidelines that recommend self-
management for people with bronchiectasis.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Self-management compared to usual care for bronchiectasis
Patient or population: people with non-cyst ic f ibrosis bronchiectasis
Setting: community
Intervention: self -management
Comparison: usual care
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with usual care Risk with self-manage-
ment
Health- related quality
of life
assessed with: SGRQ
Scale f rom: 0 to 100,
lower score is better
Follow-up: range 6
weeks to 12 months
The mean health-re-
lated quality of lif e was
56.02 points
MD 10.27 lower
(45.15 lower to 24.61
higher)
- 20
(1 RCT)
⊕©©©
Very low1,2,3
No clear benef it or harm
f rom self -management
(very low-quality evi-
dence)
Health- related quality
of life
assessed with: SGRQ
Scale f rom: 0 to 100,
lower score is better
Follow up:
range post-intervent ion
to 6 months
The mean health-re-
lated quality of lif e was
44.7 points
MD 3.2 higher
(6.64 lower to 13.04
higher)
- 60
(1 RCT)
⊕⊕©©
Low1,3
No clear benef it or harm
f rom self -management
Exacerbations requir-
ing antibiotics
- - - - - Not reported
Serious adverse
events: mortality
- - not est imable 20
(1 RCT)
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Hospital admissions
(number admitted at
least once)
Follow-up: range 6
weeks to 12 months
- - not est imable 20
(1 RCT)
-
Lung function as-
sessed with: FEV1 L
Follow-up: discharge to
12 months
The mean FEV1 was 1.
03 L
MD 0.3 higher
(1.11 lower to 1.71
higher)
- 20
(1 RCT)
⊕©©©
Very low1,2,3
No clear benef it or harm
f rom self -management
Self- efficacy assessed
with: CDSS
Scale f rom: 0 to 10
Follow-up: post inter-
vent ion to 6 months
- - not est imable 60
(1 RCT)
⊕⊕©©
Low1,3
Six out of ten scales
showed signif icant im-
provements over t ime
with the intervent ion.
We elected not to in-
clude all 10 scales in
the table but graded
the evidence based on
overall quality of the
study
Economic costs - - - - - Not reported
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CDSS: Chronic Disease Self -ef f icacy Scale; CI: conf idence interval; FEV1 : f orced expiratory volume in one second MD: mean dif ference; SGRQ: St George’s Respiratory
Quest ionnaire
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1One point deducted for the unblinded nature of the comparison.5
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2One point deducted for baseline imbalances.
3One point deducted for risk of bias f rom an underpowered study. Figure 1
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B A C K G R O U N D
Description of the condition
Bronchiectasis, also referred to as non-cystic fibrosis (non-CF)
bronchiectasis, is a persistent respiratory condition characterised
by abnormal dilation of the airways (Pasteur 2010; Chang 2015).
Pathological processes include weakness and destruction of the
structural components of the bronchial wall, which together with
the loss of ciliated epithelium, and increase in number and hyper-
trophy of mucus-secreting glands, causes mucus to accumulate,
which in turn creates a conducive environment for bacteria and
leads to a ‘vicious cycle’ of bacterial infection (Cole 1986), in-
flammatory mediator release, airway damage and further infection
(Welsh 2015). Chronic infection is associated with a variety of
pathogens (Martinez-García 2007;Murray 2011; Chalmers 2012;
Tunney 2013), contributing to persistent symptoms and repeated
exacerbations (Murray 2011).
Causes of bronchiectasis include a wide range of factors such as
damage by serious infection (including Mycobacterium tubercu-
losis), necrotising pneumonia, immune deficiency, allergic bron-
chopulmonary aspergillosis, and recurrent aspiration, although
the majority of cases are idiopathic (Pasteur 2000; Goeminne
2012; Lonni 2015). Diagnosis is based on clinico-radiographic
assessments, requiring identification of one or more abnormally
dilated bronchi using high-resolution computerised tomography
(HRCT) scanning and appropriate symptoms, including chronic
productive or wet cough and recurrent lower respiratory tract
infections, together with a range of other symptoms such as
breathlessness, wheeze, chest pain (in stable patients) and lethargy
(Pasteur 2010; Chang 2015). Factors associated with disease
severity include frequency of hospital admissions and mortality,
poor lung function, bacterial colonisation, high Medical Research
Council (MRC) dyspnoea score and frequency of exacerbations
(Chalmers 2014; Martinez-García 2014). The impact on people’s
quality of life is significant and health status is poor with pro-
gressive deterioration. Severity may be assessed with tools such as
the Bronchiectasis Severity Index (Chalmers 2014), or FACED
(FEV1, Age, Chronic colonisation, Extension (number of lobes),
Dyspnoea) (Martinez-García 2014), to identify high-risk individ-
uals, though they have limited value as outcome measures because
of the non-modifiable nature of components such as lung func-
tion.
Estimates of the prevalence of bronchiectasis vary considerably.
Although it has previously been considered a relatively rare disease
(Kolbe 1996), more recent studies have suggested an increasing
prevalence, particularly in those over 75 years (Weycker 2005),
and higher prevalence rates in low-income and middle-income
countries (Habesoglu 2011). Co-morbidity may also influence
detection and prevalence, with one UK study showing that 29%
of people with COPD scanned by HRCT had bronchiectasis (
O’Brien 2000). Prevalence rates per 100,000 were estimated at 0.5
in Finland and 3.7 in New Zealand though these data are more
than 10 years old (European Lung White Book 2013). Higher
prevalence rates have been observed in ethnic populations such as
amongst indigenous Australians (up to 14 per 1000) and Native
Alaskan children (up to 20.5 per 1000) (Singleton 2000; Chang
2002). Higher prevalence rates are also observed in women and
people aged over 60 years (Chang 2003; Seitz 2012). Recent data
suggest that incidence and prevalence in the UK may be higher
than previously estimated (Quint 2016). Over a nine-year period
to 2013, point prevalence rates per 100,000 rose from 350.5 to
566.1 in women and from 301.2 to 485.5 in men. This reflects
an increase of more than 60% with approximately 263,000 adults
living with bronchiectasis in 2013. Similarly, the incidence rates
per 100,000 person-years rose from 21.2 to 35.2 in women and
from 18.2 to 26.9 in men, a 63% increase in new cases to over
15,000 in 2013. However, these increases may be due to improved
diagnosis resulting from easier access to high-quality CT scanners,
rather than a true rise in prevalence (Goeminne 2016).
Mortality rates for bronchiectasis in England and Wales rose by
3% per year between 2001 to 2007 (Roberts 2010), and hospi-
talisations also increased by 3% per year over a nine-year period
in the US (Seitz 2010). Average bronchiectasis mortality rates per
100,000 general population in Europe are estimated at 0.3 in 27
of the 28 countries in the EU (ranging from 0.01 in Germany to
1.18 in the UK) and 0.2 in nine non-EU countries (ranging from
0.01 in Azerbaijan to 0.67 in Kyrgyzstan), based on 2005 to 2009
data (European Lung White Book 2013). The recent UK study
reported higher age-adjusted bronchiectasis mortality rates, with
estimates 2.26 times higher in women and 2.14 times higher in
men compared to the general population (Quint 2016).
The main aims of therapeutic management are: preservation of
lung function, reduction of symptoms and exacerbations, min-
imising complications, and improvement in quality of life (Pasteur
2010; Saleh 2014; Chang 2015).
Description of the intervention
Taylor 2014 describes a taxonomy in which long-term conditions
are diagnosed and brought under control by professionals; there-
after the individual self-manages the condition with support, to
achieve stable maintenance. Self-management support empowers
the person with the condition by enabling them to modify treat-
ment or behaviour, or to seek professional advice and has been
defined as “increasing the capacity, confidence, and efficacy of
the individual” (Kennedy 2013). Self-management interventions
are defined as structured programmes for individuals, designed to
improve self-health behaviours and self-management skills (Lorig
2003). Self-management programmes should ideally include train-
ing with feedback to improve problem solving, decision making,
resource utilisation, formation of patient-provider partnerships,
action planning and self-tailoring (Lorig 2003). People become
more confident at managing their own health and this in turn
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supports the development and maintenance of beneficial health
behaviours (Lorig 2003; Bourbeau 2004).
Self-management support is delivered in a range of ways, all of
which aim to equip the individual with knowledge, ability, and
confidence, to take appropriate action. The support can take
the form of specific techniques employed to help people choose
healthy behaviours, but it can also be a fundamental alteration
of the patient-caregiver relationship into a collaborative partner-
ship (de Silva 2011). Interventions can range from individualised
support such as the provision of educational material, to larger
but localised whole-system approaches. An example of a whole-
system approach involved practitioners trained to offer a range of
resources, such as a tool to assess the support needs of patients,
guidebooks on self-management, and a web-based directory of
local self-management resources (Kennedy 2013). There are also
extensive generic programmes such as the ‘Expert Patients Pro-
gramme’ (Department of Health 2001).
Self-management support increasingly includes amutually agreed,
individualised plan, which incorporates behavioural elements in-
cluding goal setting and problem solving. Recent work conducted
by the Richmond Group of Charities and The King’s Fund sug-
gests that clients and professionals should co-create a personalised
self-management plan which could include patient and career ed-
ucation, medicines’ management advice and support, use of tele-
care and telehealth to aid self-monitoring, psychological inter-
ventions (e.g. coaching), telephone-based health coaching, symp-
tom management and patient access to their own records (Naylor
2015). Self-management support and interventions can therefore
vary significantly. All approaches aim to enable the individual to
develop the knowledge and confidence to appropriately manage
their long-term condition, and to seek professional support when
needed.
The components of self-management programmes may need to
be condition-specific; for example, education may be particularly
beneficial for diabetes, but cognitive and behavioural interven-
tions may work well for people with depression (de Silva 2011).
The principal aims of management in bronchiectasis are to main-
tain and improve pulmonary function and to improve quality
of life by reducing symptoms and exacerbations (Pasteur 2010;
Chang 2015). British Thoracic Society guidelines recommend a
range of therapeutic strategies including physiotherapy for air-
way clearance, pulmonary rehabilitation for significant dyspnoea,
bronchodilators for reversible airflow obstruction and a range of
antibiotic therapy to reduce bacterial load. The latter may include
short-term courses for exacerbations, prophylactic therapy for fre-
quent exacerbators (≥ 3 exacerbations requiring antibiotics per
year) and combination therapy for people with multiple airway
pathogens (Pasteur 2010). Recommendations are often based on
a small number of short trials that are insufficient to draw firm
conclusions about benefits and harms (Welsh 2015).
Bronchiectasis impacts upon physical and psychosocial well-being
and there is the potential to improve self-management through
self-regulation of medication, adherence to airway clearance tech-
niques and patient education about management of the condition
(Wilson 1997; Lavery 2007). Current guidelines recommend air-
way clearance techniques, adherence to medication, action plans,
exercise (including pulmonary rehabilitation), and patient educa-
tion as potential components of self-management interventions
for bronchiectasis (Pasteur 2010; Chang 2015). The educational
component focuses on understanding the basic principles of dis-
ease management and early recognition of an exacerbation to fa-
cilitate timely intervention (Pasteur 2010). In COPD, self-man-
agement programmes that include action plans have been shown
to accelerate appropriate treatment-seeking behaviours (Walters
2010), and studies including action plans should therefore be con-
sidered separately.
How the intervention might work
Studies of long-term chronic conditions suggest that self-manage-
ment support may improve self-efficacy, health status, psycholog-
ical well-being, coping strategies and physical functioning (Farrell
2004; Griffiths 2005; Siu 2007; Challis 2010). Benefits may be
attributable to enhanced adherence to medication, the adoption
of appropriate behaviours, and reduced stress and anxiety, though
this may also be associated with increased use of healthcare re-
sources (Naylor 2015). Self-management programmes for COPD,
defined above, have improved quality of life and reduced breath-
lessness and hospital admissions (Zwerink 2014), though there is
currently no consensus on the most effective components of self-
management interventions (Effing 2012). The evidence of effec-
tiveness in cystic fibrosis is less clear, with interpretation of ob-
served increases in knowledge and changes in behaviour hampered
by small, poor-quality trials (Savage 2014).
The objectives of care in bronchiectasis are to treat identifiable
underlying causes, control symptoms, reduce the number of ex-
acerbations, prevent deterioration in pulmonary function, im-
prove quality of life and minimise complications (Pasteur 2010;
Chalmers 2016). The potential benefits from self-management in
individuals with bronchiectasis may include: reduction in symp-
toms and subsequent improvement in quality of life; and reduc-
tion in the number and severity of exacerbations, together with
potential reduction in hospital admissions, length of stay, and dis-
ease and health status decline.
Non-adherence to therapy may be a significant problem in
bronchiectasis with up to 50% of people with severe chest in-
fections not completing prescribed courses of antibiotics, other
medicines and airway clearance (McCullough 2014). People who
do not adhere to therapy have a shorter time to first exacerbation
(Haworth 2014); and a higher annual exacerbation rate compared
to those who are adherent (McCullough 2014). Similar to reports
from cystic fibrosis (Sawicki 2009), treatment burdenmay increase
with the emergence of new treatments, which may in turn lead
to more problems with adherence. Non-adherence to antibiotic
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therapy and airway clearance procedures may be attributable to a
range of factors including beliefs about their potential risks and
benefits, a younger age and (for antibiotics) a higher number of
prescribed medications (McCullough 2015). It is likely that pa-
tient self-management programmes may help to improve adher-
ence to prescribed therapy and reduce the negative consequences
of poor adherence. With the rise of antimicrobial resistance, ad-
herence to frontline antibiotic therapy may be particularly impor-
tant for people with bronchiectasis (O’Neill 2016).
Why it is important to do this review
Bronchiectasis is a chronic disease which causes both persistent
day-to-day symptoms such as cough and breathlessness, and inter-
current exacerbations. The long-term management of bronchiec-
tasis focuses on reducing these features of the disease.
Self-management interventions have been shown to be benefi-
cial in the management of other airways diseases associated with
management of day-to-day respiratory symptoms and respira-
tory exacerbations such as asthma and COPD (Zwerink 2014;
Peytremann-Bridevaux 2015). Guidelines recommend self-man-
agement plans for these diseases and patient education is one of
the factors in bronchiectasis management recently prioritised by
the European EMBARC group (Aliberti 2016).
This review aims to summarise the evidence for self-management
strategies for people with bronchiectasis and will seek to provide
guidance for both current recommendations and possible future
research needs.
O B J E C T I V E S
To assess the efficacy, cost-effectiveness and adverse effects of self-
management interventions for adults and children with non-cystic
fibrosis bronchiectasis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included parallel and cluster-randomised controlled trials
(RCTs) of any duration. We included studies reported as full-text,
those published as abstract only, and unpublished data.
Types of participants
Adults (> 18 years) and children with a diagnosis of non-cystic
fibrosis bronchiectasis confirmed by plain film chest radiograph,
bronchography or high-resolution computed tomography with at
least three months of daily sputum expectoration. We excluded
participants with a diagnosis of cystic fibrosis (CF), sarcoidosis or
active allergic bronchopulmonary aspergillosis. We also excluded
studies of other long-term health conditions unless results for peo-
ple with bronchiectasis were reported separately.
Types of interventions
Self-management interventions were defined as structured inter-
ventions for individuals with bronchiectasis designed to improve
self-health behaviours and self-management skills. We specified
that interventions should include collaborative interaction be-
tween participants and healthcare providers, involving goal setting
and feedback, with at least two points of contact, and that specific
programmes should include at least two of the following compo-
nents: patient education, airway clearance techniques, adherence
to medication, exercise (including pulmonary rehabilitation), and
action plans (Pasteur 2010; Chang 2015). Self-management in-
terventions that included action plans were to be considered sepa-
rately (Hagger 2014). We excluded interventions solely compris-
ing participant education or those focused only on exercise, such as
pulmonary rehabilitation delivered in a care setting. We included
pulmonary rehabilitation interventions only when they explicitly
included self-management strategies within the programme. We
included studies of self-management interventions delivered in
any form (e.g. Internet, mobile device, face-to-face, paper) with
the following comparisons.
1. Self-management versus usual care
2. Self-management versus an alternate form of self-
management (e.g. paper-based booklet versus mobile app)
For comparisons between different types of self-management pro-
grammes we included co-interventions, including types of exercise
interventions, provided that they were evenly distributed between
groups.
Types of outcome measures
We included all outcomes irrespective of follow-up duration, but
planned to evaluate the impact of follow-up in subgroup analyses
if sufficient data were available.
Primary outcomes
1. Health-related quality of life using measures validated for
people with bronchiectasis in a clinical setting (e.g.
Bronchiectasis Severity Index (BSI; St. George’s Respiratory
Questionnaire (SGRQ))
2. Exacerbations (requiring antibiotic therapy) measured as
frequency, proportion with one or more, or duration
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3. Serious adverse events (i.e. any adverse even that results in
death or is life-threatening)
Secondary outcomes
1. Frequency of hospital admissions measured
2. Lung function (forced expiratory volume in one second
(FEV1) litres or percent of predicted)
3. Symptoms (e.g. dyspnoea, cough, wheeze), for example
using the Leicester Cough Questionnaire (LCQ)
4. Self-efficacy (e.g. Chronic Disease Self-Efficacy Scale)
5. Economic costs (e.g. direct: costs of care such as cost-
benefit or cost-effectiveness; indirect: days lost from work or full-
time education)
6. Adverse events (e.g. pneumonia)
Reporting of one or more of the outcomes above was not an in-
clusion criterion for the review.
We recognise the limitation of using self-efficacy as a primary out-
come, and itmay be viewed as an intermediate or process outcome.
Research is needed to establish if, in bronchiectasis, improvements
in self-efficacy leads to long-term improvements in clinically im-
portant endpoints (Lavery 2011).
Search methods for identification of studies
Electronic searches
We identified studies from the Cochrane Airways Trials Register,
which is maintained by the Information Specialist for the Group.
The Cochrane Airways Trials Register contains studies identified
from several sources:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL), through the Cochrane Register
of Studies Online (crso.cochrane.org);
2. weekly searches of MEDLINE Ovid SP 1946 to date;
3. weekly searches of Embase Ovid SP 1974 to date;
4. Monthly searches of PsycINFO Ovid SP 1967 to date;
5. Monthly searches of CINAHL EBSCO (Cumulative Index
to Nursing and Allied Health Literature) 1937 to date;
6. Monthly searches of AMED EBSCO (Allied and
Complementary Medicine);
7. handsearches of the proceedings of major respiratory
conferences.
Studies contained in the Trials Register are identified through
search strategies based on the scope of Cochrane Airways. Details
of these strategies, as well as a list of handsearched conference pro-
ceedings are in Appendix 1. See Appendix 2 for search terms used
to identify studies for this review.
We also conducted a search of
ClinicalTrials.gov (www.ClinicalTrials.gov) and theWorld Health
Organization (WHO) trials portal (www.who.int/ictrp/en/). We
searched for studies in any language in all databases from their
inception to November 2016.
Searching other resources
We examined the reference lists of all primary studies and review
articles for additional references and searched relevantmanufactur-
ers’ websites for trial information. We searched the ‘grey’ literature
at OpenGrey (www.opengrey.eu/) and searched for errata or re-
tractions from included studies published in full-text on PubMed
(www.ncbi.nlm.nih.gov/pubmed).
Data collection and analysis
Selection of studies
Two review authors (CK and SG) independently screened titles
and abstracts for inclusion of all potential studies and classified
them as ’retrieve’ (eligible or potentially eligible/unclear) or ’do not
retrieve’. Two review authors (CK and S Grundy) independently
screened the full-text of retrieved studies to identify those for in-
clusion and record reasons for exclusion of the ineligible studies.
We resolved disagreements through discussion or through a third
review author (SS). We identified and excluded duplicates and
collated multiple reports of the same study so that each study,
rather than each report, was the unit of interest in the review. We
recorded the selection process in sufficient detail to complete a
PRISMA flow diagram and a ’Characteristics of excluded studies’
table (Moher 2009).
Data extraction and management
We used a data collection form, piloted on at least one study in
the review, to record study characteristics and outcome data. One
review author (DL) extracted the following characteristics from
the included studies.
1. Methods: study design, total duration of study, details of
any ’run in’ period, number of study centres and location, study
setting, withdrawals, and date of study
2. Participants: number, mean age, age range, gender, severity
of condition, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria, and exclusion criteria
3. Interventions: intervention, comparison, concomitant
medications, and excluded medications
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported
5. Notes: funding for trial, and notable conflicts of interest of
trial authors
Two review authors (DL and CK) independently extracted out-
come data from the included studies. We noted outcome data
that were not reported in a usable way in the ’Characteristics of
included studies’ table. We resolved disagreements by consensus
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or by involving a third review author (SS). One review author
(DJWE) transferred data into the Review Manager 5 (RevMan 5)
file (RevMan 2014). We validated data entry by comparing the
data presented in the systematic review with the study reports. A
second review author (CK) spot-checked study characteristics for
accuracy against the trial report.
Assessment of risk of bias in included studies
Two review authors (CK and DL) independently assessed the risk
of bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011a).
We resolved disagreements by discussion or by involving another
review author (SS). We assessed the risk of bias according to the
following domains.
1. Random sequence generation
2. Allocation concealment
3. Blinding of participants and personnel
4. Blinding of outcome assessment
5. Incomplete outcome data
6. Selective outcome reporting
7. Other bias
We graded each potential source of bias as high, low or unclear and
provided a quote from the study report together with a justifica-
tion for our judgement in the ’Risk of bias’ table. We summarised
the risk of bias judgements across different studies for each of the
domains listed and considered blinding separately for different
key outcomes where necessary (e.g. for unblinded outcome assess-
ment, risk of bias for all-cause mortality may be very different than
for a patient-reported quality-of-life scale). Where information on
risk of bias related to unpublished data or correspondence with a
trialist, we noted this in the ’Risk of bias’ table.
When considering treatment effects, we took into account the risk
of bias for studies that contributed to that outcome.
Assessment of bias in conducting the systematic
review
We conducted the review according to the published protocol
and reported any deviations from it in the ’Differences between
protocol and review’ section of the systematic review.
Measures of treatment effect
We estimated intervention effects using odds ratios with 95% con-
fidence intervals (CI) for dichotomous data and mean difference
or standardised mean difference with 95%CI for continuous data.
Where standard deviations (SD) were not reported but other mea-
sures of variance around mean differences, such as standard error,
CIs, or P values were reported, we calculated these according to
Section 7.3 in the Cochrane Handbook for Systematic Reviews of In-
terventions (Higgins 2011b). In this review it was likely that differ-
ent scales may have been used to measure the same outcome (for
example, Bronchiectasis-Quality of Life (B-QoL) and St. George’s
Respiratory Questionnaire (SGRQ)). In this case, we planned to
use the standardised mean difference (SMD) and its 95% CI, en-
suring a consistent direction of effect by reversing scaling where
necessary, supported by a statement in the text on direction of
interpretation.
We planned to undertakemeta-analyses only where this wasmean-
ingful, that is, where the treatments, participants and the under-
lying clinical question were similar enough for pooling to make
sense. We planned to narratively describe skewed data reported as
medians and interquartile ranges.
Unit of analysis issues
In this review the unit of analysis was the participant. For all
dichotomous data, we reported the proportion of participants that
contributed to each outcome compared with the total number of
randomised participants.
Cross-over trials
Cross-over trials were not appropriate for this intervention as it
was not possible to avoid carry-over of knowledge acquisition from
the first phase. However, if we had identified eligible cross-over
studies we planned to only include data from the first pre cross-
over phase.
Cluster-randomised trials
Large-scale trials are uncommon in bronchiectasis and it was there-
fore unlikely that we would identify eligible RCTs randomising at
group level (e.g. by primary care practice). We planned to anal-
yse eligible cluster-RCTs in accordance with methods described
in Section 16.3 of the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011c), using average cluster size and an
estimate of the intraclass correlation coefficient (ICC) to adjust
sample sizes to the ’effective sample size’. Where appropriate, we
planned to combine single RCTs with cluster-RCTs if we con-
sidered the designs and interventions sufficiently similar and the
effect of the intervention was unlikely to be influenced by the
method of randomisation.
Multiple-arm trials
Where trials included multiple arms we planned to describe all
study groups in the ’Characteristics of included studies’ table, but
to only include the arms that met our review criteria in the anal-
yses. If multiple comparisons (e.g. self-management A versus self-
management B versus self-management C versus usual care) were
combined in the same meta-analysis, we planned to divide the
usual care (control) group by the number of intervention arms to
avoid ’double-counting’.
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Dealing with missing data
We contacted investigators of included studies to provide unre-
ported data such as missing outcomes, missing data, means or SDs
and noted differential dropout between study groups along with
reasons for withdrawal. Where a particular outcome included sub-
stantial loss to follow-up (≥ 50%), we planned to report this in
the text andmark the data with an asterisk.We used available cases
for data analysis and did not impute missing data. Where studies
included analyses based on the imputation of missing values, we
planned to include data at low risk of bias and report data sep-
arately for those at higher risk of bias in the text of the review.
Multiple imputation methods that included sensitivity analyses
pre-specified in published protocols were considered at low risk of
bias (Little 2012; Gewandter 2014). Imputation of missing data
related to trial outcomes, using methods such as last observation
carried forward, were not considered appropriate. For example,
completion of missing data (e.g. relating to an efficacy outcome)
following an intervention-related death would be inappropriate
(Gewandter 2014).
Where missing data were thought to introduce a high risk of bias
(substantial loss to follow-up or inappropriate imputation), we
planned to explore the impact of including such studies using a
sensitivity analysis.
Assessment of heterogeneity
In this review, the specific nature of the intervention, population,
outcomes and methodological quality had the potential to vary
considerably between studies. We therefore planned to assess po-
tential sources of variability between studies in the following ways.
1. Clinical variability: to compare the distribution of
participants, interventions, and outcomes across the included
studies. To discuss and agree potential clinical heterogeneity by
consensus.
2. Methodological variability: to compare study designs and
study quality using ’Risk of bias’ criteria.
3. Statistical heterogeneity (where variability in the effects of
interventions is greater than expected by chance alone): to
evaluate the statistical significance of heterogeneity using the
Chi² test (P = 0.10 is significant). However, this test may be
unreliable, lacking power to detect important heterogeneity with
few or small studies and the potential to detect clinically
insignificant heterogeneity with large numbers of studies. It is
also possible for trials to show large consistent effects in the face
of significant heterogeneity. Therefore, in addition to assessing
evidence of heterogeneity using the Chi² test as above, we also
planned to quantify the magnitude of heterogeneity using the
Tau² (random-effects model only), and I² statistics (Higgins
2003) with the following interpretation thresholds, based on
recommendations in Section 9.5 of the Cochrane Handbook for
Systematic Reviews of Interventions (Deeks 2011):
i) 0% to 40%: might not be important;
ii) 30% to 60%: may represent moderate heterogeneity;
iii) 50% to 90%: may represent substantial heterogeneity;
iv) 75% to 100%: considerable heterogeneity.
We planned to report substantial heterogeneity (> 50%) and to
explore possible causes by prespecified subgroup analysis.
Assessment of reporting biases
We planned to compare the results of data from published and
unpublished studies as a direct test of publication bias and, if there
were a sufficient number of studies (10 or more), to explore poten-
tial bias arising from small-study effects using Egger’s method to
test for asymmetry in funnel plots (Egger 1997). If smaller stud-
ies had shown larger intervention effects compared to larger stud-
ies, we planned to evaluate potential causes (for example, poor
methodological quality; differences in populations or interven-
tions) and to report studies at high risk of bias in the text of the
review.
Data synthesis
We planned to include studies in meta-analyses where the study
designs, interventions and outcomes were similar. Where substan-
tial heterogeneity (> 50%)was identifiedwe planned to report out-
comes in the text, giving direction and size of the effect along with
the strength of the evidence (risk of bias). It was likely that included
studies would vary by population, design and outcomes, there-
fore we considered meta-analysis using a random-effects model
the most appropriate. However, where there are few studies or the
effects of interventions across studies are not randomly distributed
(for example, with publication bias), the random-effects model
estimates may be unreliable or biased. It was likely that this review
would only include a small number of low-powered studies and
we therefore planned to use a fixed-effect model and to evaluate
the impact of model choice using a sensitivity analysis. We aimed
to synthesise and report dichotomous and continuous data sepa-
rately for a given outcome, should the need arise (e.g. exacerba-
tion/no exacerbation or exacerbation duration). Where both end-
of-study point estimates and change from baseline scores were re-
ported we analysed these separately. We performed the analyses
using RevMan 5 (RevMan 2014).
’Summary of findings’ table
We created a ’Summary of findings’ table using the following
primary and secondary outcomes: health-related quality of life,
hospital admissions, serious adverse events, exacerbations, lung
function, self-efficacy and economic costs.We tabulated the qual-
ity of each outcome with the five GRADE criteria (study limi-
tations, consistency of effect, imprecision, indirectness and pub-
lication bias) (GRADE 2004) using methods and recommenda-
tions described in Section 8.5 (Higgins 2011a) and Chapter 12
(Schünemann 2011) of the Cochrane Handbook for Systematic Re-
views of Interventions andGRADEproGDTsoftware (GRADEpro
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GDT 2015). We justified all decisions to downgrade or upgrade
the quality of studies using footnotes and we included comments
to aid the reader’s understanding where necessary.
Subgroup analysis and investigation of heterogeneity
We planned to carry out the following subgroup analyses.
1. Age: adults (> 18 years) versus children
2. Duration of follow-up (less than 12 months versus 12
months or longer)
We planned to use the following outcomes in subgroup analyses.
1. Health-related quality of life
2. Hospital admissions
3. Adverse events
We planned to use the formal test for subgroup interactions in
RevMan 5 (RevMan 2014).
Sensitivity analysis
We planned to carry out the following sensitivity analyses.
1. To exclude studies at high risk of selection bias
2. Analyses using a random-effects model
3. Missing data (studies with > 50% or those using
inappropriate imputation)
R E S U L T S
Description of studies
Results of the search
Following comprehensive electronic searches of bibliographic
databases we identified ninety-two records and an additional eight
records through searches of clinicaltrials.gov and the WHO trials
portal. Of a total of sixty records (40 duplicates removed), forty-
three were excluded following screening of titles and abstracts. We
examined the full-text articles of 17 records (11 studies) and ex-
cluded 12 records (8 studies; see Excluded studies). The remain-
ing five records reported the results of three studies; two stud-
ies were included in the review and one was an ongoing study
(Characteristics of ongoing studies). The PRISMA flow diagram
in Figure 2 shows the study selection process.
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Figure 2. Study flow diagram
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Included studies
Two studies met the inclusion criteria for this review and con-
tributed data to the narrative synthesis (Lavery 2011; Greening
2014). The two studies randomised a total of 84 adult partici-
pants with bronchiectasis. Greening 2014 recruited and reported
data for participants with any respiratory disease (n = 389), but
the study authors kindly provided disaggregated data for the sub-
set of participants with a primary diagnosis of bronchiectasis that
are reported in the review. Both studies were reported as full-text,
peer-reviewed articles. In Greening 2014 the complex rehabilita-
tion intervention included a self-management programme. As this
component of the complex intervention was substantial, we have
included the trial in this review; however, we are mindful that
because the self-management programme was included alongside
other interventional components (described in Characteristics of
included studies) the findings from this trial in relation to the
predefined inclusion criteria for this review should be interpreted
with caution.
Methods
Greening 2014 was a prospective, 12-month RCT conducted in
an acute cardiorespiratory unit in a teaching hospital and an acute
medical unit in an affiliated teaching district general hospital, both
located in England (UK) Characteristics of included studies.
Lavery 2011was a proof-of-concept, six-monthRCT in a single re-
gional respiratory centre in Northern Ireland (UK)Characteristics
of included studies.
Participants
Greening 2014 enrolled adults with a diagnosis of chronic respira-
tory disease, aged 40 years or over (bronchiectasis group mean age
= 72 (intervention = 78, control = 68) with self-reported breath-
lessness on exertion (MRC dyspnoea grade 3 or worse). Individu-
als with concomitant acute cardiac events or more than four emer-
gency admissions to hospital (any cause) during the previous 12
months were excluded. Eligible patients were enrolled within 48
hours of admission to hospital for an exacerbation of chronic res-
piratory disease. The study included people with COPD, chronic
asthma, interstitial lung disease and bronchiectasis but the study
authors kindly provided disaggregated data for the cohort of par-
ticipants with bronchiectasis (n = 20); baseline characteristics are
presented in the Characteristics of included studies.
In Lavery 2011 64 adult participants were randomised (with 32
participants in each arm of the study), and four were withdrawn
before the study reached completion (two in each arm of the
study). In both groups the mean age was 60 years, with an inclu-
sion criterion of 18 years or over, and with a primary diagnosis
of bronchiectasis based on respiratory physician assessment, in-
cluding a computed tomographic scan Characteristics of included
studies
Interventions
Greening 2014 randomised individuals on a 1:1 basis to receive
early rehabilitationplus self-management (sixweeks’ duration) and
usual care, versus usual care alone. Early rehabilitation comprised
supervised volitional (strength and aerobic training) and non-voli-
tional (neuromuscular electrical stimulation) techniques and a self-
management programme. The progressive exercise programme
was individually tailored and delivered/supported by physiother-
apists and nurses during the stay on an acute medical ward, and
after discharge was supported by weekly telephone consultations
with the pulmonary rehabilitation team, consisting of physiother-
apists and nurses. The self-management programme comprised
the SPACE (Selfmanagement programme of Activity, Coping and
Education) manual for COPD, a structured programme of exer-
cise, education, and psychosocial support.Motivational interview-
ing techniques were used to familiarise participants with the man-
ual, which was used throughout the participants’ inpatient stay
and during telephone discussions. Usual care comprised standard
care from the ward physiotherapy team, including physiothera-
pist-delivered techniques for airway clearance, assessment and su-
pervision of mobility and smoking cessation advice; usual care did
not include a supervised progressive exercise programme during
admission or immediately after discharge.
In Lavery 2011 the intervention was usual care plus an expert
patient programme (EPP); disease-specific EPP was delivered in
group format during one session per week (2.5 hours) for eight
weeks (two weeks of disease-specific education; six weeks of stan-
dardised EPP). The disease-specific component included causes
of bronchiectasis, disease process, medical investigations, dealing
with symptoms, airway clearance techniques, exacerbations, health
promotion and available support. Participants in the control group
received usual care; review at a specialist respiratory clinic on a
three-monthly basis to monitor spirometry, inflammatory blood
markers, and sputum microbiologic assessment. Inhaled therapy
and antibiotics were prescribed where required and treatment was
adjusted to the needs of the participant as necessary, including
hospital admission.
Outcomes
The primary outcome for the study reported by Greening 2014
was the readmission rate at 12 months. Secondary outcomes in-
cluded number of hospital days, mortality, lung function, physical
performance and health-related quality of life, measured using the
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St George’s Respiratory Questionnaire (SGRQ); secondary out-
comes were assessed at baseline, discharge from hospital, six-week,
and three- and 12-month follow-up.
In Lavery 2011 the primary outcome was the Chronic Disease
Self-efficacy Scales (CDSS), which measures the confidence of
an individual to perform items related to self-management. Sec-
ondary outcomes included the Revised Illness Perception Ques-
tionairre (IPQ-R), which explains health behaviour in terms of
coping; SGRQ was used to measure quality of life; two standard
EPP questionnaires relating to self-rated health, ability to man-
age their condition and adherence to medication. Other outcome
measures included FEV1, frequency of antibiotic therapy and spu-
tum microbiology. Secondary measures were recorded at baseline,
post-intervention (eight weeks) and at three- and six-month fol-
low-up.
Excluded studies
We excluded a total of eight studies (Newall 2005; Liaw 2011;
Mandal 2012; Gurses 2013; Lee 2014; Mazzoleni 2014 ;Hester
2016; Aksamit 2017; ); three studies were excluded because both
intervention and control groups received common self-manage-
ment components (Newall 2005;Mandal 2012; Lee 2014), result-
ing in a single component of difference between the two groups,
which failed to meet our inclusion criteria of at least two elements
in the self-management component; the intervention in one study
was solely an information resource, which also did not meet our
criteria (Hester 2016); in three studies the intervention was not
self-management (Liaw 2011; Gurses 2013;Aksamit 2017; ); in
one study with a mixed population of participants, data were not
available for bronchiectasis participants alone (Mazzoleni 2014).
Risk of bias in included studies
’Risk of bias’ assessments and supporting evidence are presented
in the Characteristics of included studies. Figure 1 provides a sum-
mary of risk of bias judgements presented by study and domain.
Figure 3 depicts the risk of bias for each domain, presented as
percentage values across both included studies. Overall, the two
included studies were well reported and of high methodological
quality; we considered the studies to have a low risk of bias for the
majority of domains (see below).
Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
Both studies used appropriate methods for random sequence gen-
eration and allocation concealment. We judged both studies to be
at low risk of selection bias.
Blinding
Blinding of the participants and personnel (i.e. those delivering the
intervention) to treatment allocation was not feasible due to the
nature of the interventions. Thus, we considered both studies to be
at low risk of performance bias for objective outcomes (i.e. exacer-
bations, serious adverse events, serious adverse events, lung func-
tion, frequency of hospital admissions, lung function, economic
costs, adverse events) and at high risk of performance bias for
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subjective outcomes (i.e. health-related quality of life; symptoms,
self-efficacy). In both studies, outcome assessors were blinded to
treatment allocation; we considered the risk of detection bias to
be low for both studies.
Incomplete outcome data
We considered both studies to have a low risk of attrition bias
based on low and balanced rates of participant withdrawal, which
were documented adequately in the study reports.
Selective reporting
Both studies were pre-registered on appropriate clinical trials reg-
istries, where predefined outcomes of interest were listed. Both
studies reported all pre-defined outcomes of interest and were con-
sidered to be at low risk of reporting bias.
Other potential sources of bias
The study by Lavery 2011 was a proof-of-concept RCT that did
not include a power calculation. There was therefore a risk that
negative findings were influenced by an inadequate sample size
and we considered this study at high risk of ’other bias’, though
this was not related to the methodological quality of the study.
The authors of Greening 2014 provided disaggregated data for
participants with bronchiectasis. The number of participants with
bronchiectasis was low (n = 20) and there appeared to be a base-
line imbalance in disease severity; participants in the interven-
tion group showed a trend towards higher MRC dyspnoea grades
(baseline and stable state) and worse baseline lung function (lower
FEV1); however, statistical comparisons were not available. In ad-
dition, mortality rates were imbalanced between groups in the
subset of bronchiectasis participants. We therefore considered the
study byGreening 2014 to be at high risk for ’other bias’, although
we would stress that this was not related to the methodological
quality of the overall study, and likely a result of our use of disag-
gregated data with an insufficient sample size.
Effects of interventions
See: Summary of findings for the main comparison Self-
management compared to usual care for bronchiectasis
The different nature of the interventions in the two included stud-
ies (a complex rehabilitation intervention including self-manage-
ment and a single expert patient programme) meant that meta-
analysis of the data was not appropriate and the results were there-
fore included narratively.
Primary outcomes
Health-related quality of life
The authors of Greening 2014 provided health-related quality of
life data for the subset of participants with bronchiectasis. Mean
SGRQ Total scores in both groups improved over time but were
not significantly different at six weeks’, three and 12 months’ fol-
low-up (6 weeks MD -12.70, 95% CI -30.39 to 4.99; 3 months
MD -9.15, 95% CI -28.08 to 9.78; 12 months MD -10.27, 95%
CI -45.15 to 24.61; Analysis 1.1). The mean difference between
groups at each time point exceeds the minimum clinically impor-
tant difference (MCID) of four units (Jones 2005) but confidence
intervals indicate imprecision in the effect, potentially attributable
to the low sample size (max n = 13). The study authors did not
formally report the change from baseline to 12 months and it was
not possible to calculate the change value as more than half of the
participants withdrew during the study. However, results should
be interpreted with caution due to the small sample size and un-
equal numbers of participants in each group (n = 20).
In Lavery 2011 there were no differences in SGRQ Total scores
between groups postintervention, or at three or six months’ fol-
low-up (postintervention: MD -6.50, 95% CI -16.59 to 3.59; 3
months, MD -2.60, 95% CI -12.97 to 7.77, 6 months, MD 3.20,
95% CI -6.64 to 13.04; Analysis 2.1). The study authors reported
marginal worsening in SGRQ Total scores over the six-month fol-
low-up in the intervention group (from 46.9, 95% CI 40.2 to
53.6 to 47.9, 95% CI 40.7 to 55.1) and an improvement of 6.9
units in the control group (from 51.6, 95% CI 45.0 to 58.1 to
44.7, 95% CI 37.6 to 51.7).
There is therefore no indication of benefit in health-related qual-
ity of life, based on SGRQ total scores, attributable to the inter-
vention. Using GRADE criteria we judged the quality of the evi-
dence for this outcome to be either low (Lavery 2011) or very low
(Greening 2014) Summary of findings for the main comparison.
Exacerbations (requiring antibiotic therapy)
Neither of the included studies reported data on exacerbations
requiring antibiotic therapy.
Serious adverse events
Greening 2014 provided mortality data for the subset of partic-
ipants with bronchiectasis. During the 12 months of follow-up,
four of eight participants (50%) died in the early rehabilitation
group and two of 12 participants (16.7%) died in the usual care
group. However, results should be interpreted with caution due to
the low event rate, unequal numbers of participants in each group
and small sample size (n = 20).
Lavery 2011 did not evaluate serious adverse events.
It was not possible to assess this outcome using GRADE criteria.
Secondary outcomes
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Frequency of hospital admissions
Greening 2014
The study authors provided data on hospital admissions for the
subset of participants with bronchiectasis. In the early rehabili-
tation group (n = 8), six participants (75%) were readmitted to
hospital during 12 months of follow-up; three were readmitted
once; one was readmitted twice; and two were readmitted three
times. In the usual care group (n = 12), six participants (50%)
were readmitted to hospital during the 12 months of follow-up;
four were readmitted once; one was readmitted three times; and
one was readmitted seven times. The mean (SD) number of ad-
missions per participant per 12 months in the early rehabilitation
group and usual care groups, respectively, were 1.38 (1.19) and
1.17 (2.04); there did not appear to be a significant difference be-
tween groups. However, results should be interpreted with caution
due to the low event rate, unequal numbers of participants in each
group and small sample size (n = 20).
Lavery 2011 did not evaluate the frequency of hospital admissions.
It was not possible to assess this outcome using GRADE criteria.
Lung function
Greening 2014
The study authors provided data on FEV1 (L) for the subset
of participants with bronchiectasis. Baseline measurements were
recordedwhen individuals were in a stable state. There were no sig-
nificant differences between groups at discharge, six weeks’, three
or 12 months’ follow-up (discharge MD -0.13, 95% CI -0.60 to
0.34; 6 weeks MD 0.07, 95% CI -0.55 to 0.69; 3 months MD
0.15, 95% CI -0.55 to 0.85; 12 months MD 0.30, 95% CI -
1.11 to 1.71; Analysis 1.2). Change in lung function was not for-
mally reported in the paper and it was not possible to calculate
the change value as more than half of the participants withdrew
during the study. The results should be interpreted with caution
due the low sample size at each time point (n = 17 at discharge;
n = 8 at one year), the unequal numbers of participants in each
group (intervention = 8; control = 12) and the small size of the
overall sample (n = 20).
Lavery 2011 reported no significant differences between the con-
trol and intervention groups with regard to lung function (P >
0.05) but did not report further details.
Using GRADE criteria we judged the quality of the evidence for
this outcome to be very low Summary of findings for the main
comparison.
Symptoms
Neither of the included studies reported data on symptoms.
Self-efficacy
Greening 2014 did not examine self-efficacy.
Lavery 2011 reported data on self-efficacy using an outcome mea-
sure found to be valid and reliable when tested in individuals with
long term-health conditions. The Chronic Disease Self-efficacy
Scale (CDSS) measures the confidence of an individual to per-
form self-management tasks on 10 component scales using 1 to
10 Likert responses. All scales showed significant benefit postin-
tervention (exercise,MD 2.10, 95%CI 0.89 to 3.31, Analysis 2.2;
disease information, MD 1.50, 95% CI 0.07 to 2.93, Analysis
2.3; obtaining help, MD 1.10, 95% CI 0.05 to 2.15, Analysis
2.4; communicating with physician, MD 1.10, 95% CI 0.14 to
2.06, Analysis 2.5; managing disease, MD 1.10, 95% CI 0.17
to 2.03, Analysis 2.6; doing chores, MD 2.00, 95% CI 0.78 to
3.22, Analysis 2.7; social activity, MD 2.00, 95% CI 0.84 to 3.16,
Analysis 2.8; Managing symptoms, MD 1.90, 95% CI 0.78 to
3.02, Analysis 2.9; Managing breathlessness, MD 1.50, 95% CI
0.32 to 2.68, Analysis 2.10;Managing depression, MD2.00, 95%
CI 0.91 to 3.09, Analysis 2.11), but the effect was only sustained
by the six-month endpoint on the Managing Depression scale (6
months, MD 1.30, 95% CI 0.09 to 2.51, Analysis 2.11). The
study authors report a significant improvement in self-efficacy over
time with the intervention on six of the 10 subscales of the CDSS
(exercise, disease information, doing chores, social activity, man-
aging symptoms and managing depression) though they acknowl-
edge that the greatest impact was immediately postintervention.
The authors report that four subscales did not show a significant
difference between groups over time (managing the disease, ob-
taining help, communicating with physician, managing breath-
lessness). There is no Minimum Clinically Important Difference
value for the CDSS.
As the CDSS comprises 10 component scales we opted not to
include them in the ’Summary of findings’ tables. However us-
ing GRADE criteria, we judged the quality of evidence for this
outcome as very low, based on the overall quality of the study
Summary of findings for the main comparison.
Economic costs
Neither of the included studies reported data on economic costs.
Adverse events
Neither of the included studies reported data on adverse events.
D I S C U S S I O N
Summary of main results
18Self-management for bronchiectasis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
There is insufficient evidence to draw clear conclusions as
to whether self-management interventions for people with
bronchiectasis have a significant impact on the primary outcomes
of this review, namely: health-related quality of life; frequency of
exacerbations and serious adverse events.
Only two studies fulfilled the inclusion criteria for the review.
The first evaluated the effect of a combined early rehabilitation
and self-management programme on 389 participants admitted
to hospital with acute exacerbations of chronic respiratory disease
(Greening 2014). However, we were only able to use a subset of 20
participants with bronchiectasis in the review. The second study
evaluated the impact of an expert patient self-management pro-
gramme on 64 participants with bronchiectasis (Lavery 2011). It
is important to note that theGreening study recruited participants
at an exacerbation, whilst Lavery recruited participants in stable
condition. Merging results of these two self-management plans
therefore is limited by the different clinical conditions of partic-
ipants and should be considered as an additional limitation. Par-
ticipants receiving self-management did not show any significant
benefit from the intervention in terms of health-related quality of
life by the endpoint in either study. There was a trend towards a
higher mortality rate in one very small study but no clear differ-
ence was seen.. Neither of the included studies measured exacerba-
tion frequency. In terms of our secondary outcomes, there was no
impact on the frequency of hospital admissions in one study and
no impact on lung function in either of our included studies. One
study reported self-efficacy using the CDSS and showed evidence
of improvement following an expert patient programme in six of
the ten scales that comprised the outcome measure. Neither of the
included studies reported symptoms, adverse events and economic
costs.
It is important to note that (Greening 2014) was a compound
intervention incorporating a substantial self-management compo-
nent and we included it in the review for that reason. However,
the findings from this trial in relation to the predefined inclusion
criteria for this review should be interpreted with caution as we
cannot isolate the effects of self-management from the other in-
tervention components. In addition, the self-management com-
ponent was based on a model used with people with COPD and
was not specifically tailored to people with bronchiectasis. All of
the results from this study should be interpreted with caution as
the disaggregated data were not powered to detect differences and
there were imbalances between groups.
Overall there is inadequate published data to establish with any
degree of certainty whether self-management strategies for people
with bronchiectasis have either a positive or negative impact.
Overall completeness and applicability of
evidence
The paucity of data available for inclusion in this review mandates
caution when extrapolating the findings to similar populations or
other settings. We identified only two adult studies in the review,
looking at different interventions. We did not identify any trials of
self-management programmes for children, nor any trials compar-
ing one type of self-management strategy with another. Neither of
the studies included in the review measured the frequency of ex-
acerbations requiring antibiotics, an important marker of disease
activity in bronchiectasis, symptoms, adverse events or economic
costs. As an exercise component was included in the compound
intervention in one of the studies, it would have been useful to
have included exercise performance as an outcome measure in the
review. As it stands, the evidence for the benefits and harms of self-
management interventions is incomplete and of limited applica-
bility to clinical practice.
Quality of the evidence
With guidance from the GRADE criteria we considered the qual-
ity of the evidence, where data were available for formal compari-
son, to be low or very low, and where data were available for nar-
rative inclusion we would draw similar conclusions. We are aware
of the limitations of the two included studies, in particular the
small amount of disaggregated data available for inclusion from
Greening 2014, and have summarised them in Characteristics of
included studies, Figure 2 and Figure 3. It was not possible to con-
sider publication bias through the construction of a funnel plot
due to the very small number of included studies.
Potential biases in the review process
We are aware of the potential for publication bias in this system-
atic review, as there is inevitably the concern that we may not have
found relevant unpublished trials. However, we have received ex-
cellent support from Cochrane Airways, with comprehensive and
systematic database searches, and we endeavoured to address any
study selection bias with two review authors independently eval-
uating trials for inclusion. Throughout we were careful to ensure
that this process was consistent with our predefined inclusion cri-
teria.
Agreements and disagreements with other
studies or reviews
The need for patient self-management has been identified and
included in bronchiectasis guidelines and research prioritisation
(Pasteur 2010; Aliberti 2016). However, uptake remains unclear
with aUKaudit showing that only 33%of 97 institutions provided
individualised self-management plans, and a single-centre UK au-
dit suggesting that effective personal management was achievable
without a formal self-management plan (Hill 2013; Ali 2015).
Aliberti 2016 suggest in their research priorities in bronchiectasis
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that future studies should be conducted to determine the effec-
tiveness of patient self-management and adherence to treatment;
this review supports this by revealing how little evidence currently
exists. Due to the limited data available from our review it is not
possible to assess whether effects of self-management may be ob-
served in people with bronchiectasis but planned future studies
may help to resolve the uncertainty (Hester 2016).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is inadequate published evidence to guide clinical decisions
as to the potential benefits and risks of self-management interven-
tions for people with non-cystic fibrosis bronchiectasis. The evi-
dence was limited by a number of factors including potentially un-
derpowered studies, complex interventions and limited reporting
of important measures of clinical benefit. Overall, this review has
been unable to identify sufficient evidence to resolve uncertainties
regarding the benefits of self-management in clinical practice. In
the absence of high-quality evidence it is advisable that practition-
ers adhere to current international guidelines that advocate self-
management for people with bronchiectasis Polverino 2017.
Implications for research
Currently, self-management for bronchiectasis is a broad term in-
corporating a diverse range of interventions, from complex multi-
component programmes to web-based information systems. An
international consensus statement defining the essential compo-
nents of bronchiectasis self-management is required in order to
support research replication, data synthesis and the evaluation of
efficacy. The international consensus-based definition of self-man-
agement will help to drive the standardisation of interventions in
COPD (Effing 2016), but the definition is unsuitable for use in
bronchiectasis. There is uncertainty about the potential overlap
between COPD and bronchiectasis, but resolution of this issue
may inform revision of the definition of self-management used in
future updates of the review. The taxonomy of self-management
support developed by Taylor and colleagues (Taylor 2014) may
form the basis for development of a self-management definition
for bronchiectasis, with condition-specific refinement informed
by methods from the chronic obstructive pulmonary disease self-
management definition (Effing 2016). The review authors sug-
gest that there is a clear need for a definition of self-management
in bronchiectasis that will provide a basis for future clinical trials
with enhanced homogeneity that could be included in subsequent
meta-analysis.
There are very few clinical trials in this area and those available
only include adults. Research is needed on the impact of self-man-
agement programmes in children, in particular with a focus on the
causes of bronchiectasis in children. The context of self-manage-
ment interventions may also vary from chest clinics to community
settings and this should be taken into consideration when evalu-
ating effectiveness. Likewise the clinical condition of the patient,
with regards to severity and exacerbation versus stable state should
be explicit in future studies. Statification of patients at risk of ex-
acerbations, hospital admissions, and mortality using a validated
tool such as the Bronchiectasis Severity Index (Chalmers 2014)
or the FACED score (Martinez-García 2014) can be considered
vital for future research. Few clinically important outcomes were
available for inclusion in this review and future studies should in-
cludemeasures of the frequency and duration of exacerbations, in-
cluding those requiring antibiotic therapy, adherence to antibiotic
therapy, other aspects of self-management such as airway clearance
techniques, adverse events and data on economic costs to inform
policy and clinical commissioning.
All future trials should use a robust, high-quality design, taking
the above sources of variability into consideration and ensuring
adequate sample sizes, potentially from multicentre studies, and
populations that reflect the age range of peoplewith bronchiectasis.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Greening 2014
Methods Study design: prospective RCT (single blind, parallel group; trial identifier: IS-
RCTN05557928)
Total duration of study: 12 months
’Run in’ period: none
Number of study centres and location: 2 centres; UK
Study setting: an acute cardiorespiratory unit in a teaching hospital and an acute medical
unit in an affiliated teaching district general hospital
Date of study: January 2010-September 2012
Participants Note: This study recruited participants with any chronic respiratory condition; Dr
Greening kindly provided disaggregated data for the participants with bronchiectasis
reported here
Number randomised: 20 participants with bronchiectasis randomised (early rehabili-
tation: n = 8; usual care: n = 12)
Number of withdrawals: none
Number analysed: variable per outcome
Mean age (SD), years: early rehabilitation: 78 (7.8); usual care: 68.8 (11.5)
Gender, n (%) male: early rehabilitation: NA; usual care: NA
Severity of condition
Mean (SD) baseline MRC dyspnoea grade on admission: early rehabilitation: 4.9 (0.
35); usual care: 4.4 (0.67)
Mean (SD) stable state MRC dyspnoea grade: early rehabilitation: 4.3 (0.46); usual
care: 3.5 (0.67)
Mean (SD) stable state FEV1 (L): early rehabilitation: 0.84 (0.28); usual care: 1.18 (0.
49)
Diagnostic criteria:MRC dyspnoea score; spirometry was measured to British Thoracic
Society standards
Baseline lung function: see severity of condition
Smoking history: smoker, n yes/no/ex-smoker/missing: early rehabilitation: 1/4/2/1
; usual care: 1/5/6/0
Inclusion criteria: the study recruited patients with a diagnosis of chronic respiratory
disease, including COPD; chronic asthma, bronchiectasis or interstitial lung disease);
we have considered only the subset of participants with bronchiectasis. Participants had
to be aged ≥ 40 years with self-reported breathlessness on exertion when stable (MRC
dyspnoea grade 3 or worse)
Exclusion criteria: inability to provide informed consent; concomitant acute cardiac
event; presence of musculoskeletal, neurological, or psychiatric comorbidities that would
prevent the delivery of the rehabilitation intervention; and > 4 emergency admissions to
hospital for any cause in the previous 12 months
Interventions Intervention: early rehabilitation (6 weeks’ duration), comprising usual care plus daily,
supervised volitional (strength and aerobic training) and non-volitional (neuromuscular
electrical stimulation) techniques. This complex intervention also included a self-man-
agement programme, described by the study authors as:
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Greening 2014 (Continued)
“The intervention team delivered education using the SPACE (Self management pro-
gramme of Activity, Coping and Education) manual for chronic obstructive pulmonary
disease, a structured programme of exercise, education, and psychosocial support. Mo-
tivational interviewing techniques were used to introduce patients to the manual and to
familiarise them with the content. The manual was used throughout the participants’
inpatient stay and in the subsequent discussions during telephone calls.”
As this component of the complex intervention was substantial we deemed the trial to
be eligible for inclusion in this review; however, we are mindful that because SPACE
was included alongside other components the findings from this trial in relation to
the predefined inclusion criteria for this review should be interpreted with caution. It
should also be noted that SPACE was primarily designed for COPD patients and is not
specifically targeted for bronchiectasis
The pulmonary rehabilitation team, consisting of physiotherapists and nurses, deliv-
ered the intervention. The exercise programme was individually prescribed and pro-
gressed. Early rehabilitation was performed on the acute medical ward and by the par-
ticipants’ bedside. After discharge, participants underwent an unsupervised home based
programme, supported by telephone consultations. Those who were readmitted after the
6-week intervention period did not receive a further early rehabilitation intervention
Comparison: usual care (standard care from the ward clinical physiotherapy team as
directed by the responsible clinical team) including physiotherapist-delivered techniques
for airway clearance, assessment and supervision of mobility, and advice on smoking
cessation. Nutritional status was assessed using the malnutrition universal screening tool
score in all participants, and referral for dietetic advice and nutritional support was carried
out if appropriate. No supervised or progressive exercise programme was provided during
the admission or immediately after discharge, but outpatient pulmonary rehabilitation
was offered to all participants 3 months after discharge as part of standard care
Concomitant medications: not stated
Excluded medications: not stated
Outcomes Primary outcomes (pre-specified): readmission rate at 12 months
Secondary outcomes (pre-specified): number of hospital days, mortality, physical per-
formance and HRQoL. Secondary functional measures were recorded at baseline, at
discharge from hospital, 6 weeks, 3 months and 12 months
Timepoints: 12 months
Outcomes collected: 1ll specified outcomes were collected
Notes Funding: not stated
Notable author conflicts of interest: none stated/identified
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The clinical trials unit at the Uni-
versity of Leicester coordinated randomisa-
tion by an automated internet based service
(www.sealedenvelope.com)”
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Greening 2014 (Continued)
Allocation concealment (selection bias) Low risk Quote: “The clinical trials unit at the Uni-
versity of Leicester coordinated randomisa-
tion by an automated internet based service
(www.sealedenvelope.com)”
Blinding of participants and personnel
(performance bias)
Subjective outcomes
High risk It is not feasible to blind participants to
the intervention. Knowledge of treatment
group could influence self-reporting of sub-
jective outcomes by participants
Blinding of participants and personnel
(performance bias)
Objective outcomes
Low risk Quote: “Single blind”. It is not feasible to
blind participants to the treatment group.
However, knowledge of treatment group
would be unlikely to influence objective
outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “..all investigators performing the
outcome measures were blinded to treat-
ment allocation..”
Incomplete outcome data (attrition bias)
All outcomes
Low risk During trial: 14/196 withdrew from inter-
vention group; 10/193withdrew from con-
trol group. Missing data imputed
Selective reporting (reporting bias) Low risk All pre-specified outcomes reported
Other bias High risk Baseline imbalances in age and disease
severity in the subset of participants with
bronchiectasis; participants in the control
group appeared to have less severe dis-
ease. Higher mortality with intervention in
bronchiectasis subgroup (intervention: 4/
8; control: 2/12)
Lavery 2011
Methods Study design: proof-of-concept RCT (NCT01117493).
Total duration of study: 6 months
’Run in’ period: none
Number of study centres and location: single regional respiratory centre, Belfast,
Northern Ireland, UK
Study setting: Tertiary care
Date of study: September 2006-October 2007
Participants Number randomised: 64 (32/32)
Number of withdrawals: 4 (2/2)
Number analysed: 60 (30/30)
Mean age (SD), years: intervention: 60 (9); control: 60 (8)
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Lavery 2011 (Continued)
Gender, % m/f: intervention: 44/56; control: 47/53
Diagnostic criteria: assessment by respiratory clinician
Baseline lung function -mean (SD)%predicted FEV1: intervention: 59 (20); control:
65 (23)
Smoking history: not stated
Inclusion criteria: adults (aged ≥ 18 years) with a primary diagnosis of bronchiectasis
based on a respiratory physician’s assessment, including a CT scan
Exclusion criteria: primary diagnosis of CF,MRSA infection, or a condition that would
have an impact on the assessment procedures (e.g. sensory impairment, pregnancy, lan-
guage barrier, or a factor that would prevent adherence to the self-management pro-
gramme)
Interventions Intervention: usual care plus EPP: disease-specific EPP was delivered in a group format
during 1 session/week (2.5 h) for 8 weeks in total (2 weeks of disease-specific educa-
tion; 6 weeks of standardised EPP). The disease-specific component included causes of
bronchiectasis, disease process, medical investigations, dealing with symptoms, airway
clearance techniques, exacerbations, health promotion and support available. The format
of the disease-specific EPP was delivered by a physiotherapist and a nurse with specialist
expertise in the management of bronchiectasis who were trained and followed a scripted
manual to standardise delivery. The format of the EPP was developed and piloted be-
fore this RCT. Topics included general health education, education on self-management
treatment strategies, action planning, and problem solving
Comparison: usual care: reviews at a specialist respiratory clinic on a 3-monthly basis
to monitor spirometry results, inflammatory blood marker levels, and sputum micro-
biologic assessment. Inhaled therapy and antibiotics were prescribed if required, and
treatment was adjusted to the needs of the participant as necessary, including hospital
admission
Concomitant medications: not stated
Excluded medications: not stated
Outcomes Primary outcomes (pre-specified): CDSS - comprises 10 scales as follows: exercise,
disease information, obtaining help, communication with physician, managing disease,
doing cores, social activity, managing symptoms, managing breathlessness, managing
depression. Responses are measured using a 1-10 Likert scale where higher scores indicate
greater self-efficacy. There is no Minimum Clinically Important Difference value for
these scales
Secondary outcomes (pre-specified): revised Illness Perception Questionnaire, SGRQ,
FEV1, frequency of oral and/or intravenous antibiotic therapy prescribed at respiratory
clinics
Timepoints: baseline, post-intervention (8 weeks), 3 and 6 months postintervention
Outcomes collected: all specified outcomes were collected
Notes Funding: supported by theHealth and Social Care Research andDevelopmentDivision,
Public Health Agency, Belfast, Northern Ireland
Notable author conflicts of interest: none
Risk of bias
Bias Authors’ judgement Support for judgement
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Lavery 2011 (Continued)
Random sequence generation (selection
bias)
Low risk Quote: “…computer generated concealed
randomisation process conducted by an in-
dependent person...”
Allocation concealment (selection bias) Low risk Quote “..an envelope corresponding to the
patient’s number was opened to reveal if
they were assigned to the intervention or
control group.”
Blinding of participants and personnel
(performance bias)
Subjective outcomes
High risk Not blinded and lack of blinding may
have influenced outcome (1 withdrew who
‘wanted intervention’)
Blinding of participants and personnel
(performance bias)
Objective outcomes
Low risk It is not feasible to blind participants or
personnel to the intervention. However,
knowledge of treatment group would be
unlikely to influence objective outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Data were collected by trained
health professionals who were blinded to
participants’ groups and had no other con-
tact with the participants. Study partici-
pants were requested not to disclose their
group assignment.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 6 months: 2/32 missing from intervention
group (1 illness, 1 did not complete out-
come measures); 2/32 missing from con-
trol group (1 wanted intervention, 1 dis-
liked questionnaire). Even balance between
groups
Selective reporting (reporting bias) Low risk All planned outcomes were reported. Sub-
jective outcomes were well-reported but
objective outcomes poorly reported
Other bias High risk This was a proof-of-concept study so there
was no power calculation. There is there-
fore a risk that negative findings were in-
fluenced by an inadequate sample size
CDSS: Chronic Disease Self-Efficacy Scale; CF: cystic fibrosis; COPD: chronic obstructive pulmonary disease; CT: computed to-
mographic; EPP: expert patient programme; FEV1: forced expiratory volume in one second; HRQoL: health-related quality of
life; MRC: medical research council; MRSA: methicillin-resistant Staphylococcus aureus ; NA: not applicable; RCT: randomised
controlled trial; SGRQ: St Georges Respiratory Questionnaire; SD: standard deviation.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aksamit 2017 The intervention was not self-management
Gurses 2013 Inspiratory muscle training was the sole intervention
Hester 2016 Information resource was the sole intervention
Lee 2014 Exercise programme plus airway clearance therapy (ACT) advice at baseline versus ACT advice at baseline alone.
Therefore, the only intervention component was exercise and does not meet our criteria of at least 2 components
in the intervention group alone
Liaw 2011 Inspiratory muscle training was the sole intervention
Mandal 2012 Pulmonary rehabilitation plus chest physiotherapy plus education plus self-management plan versus chest physio-
therapy plus education plus self-management. Therefore, the only component in the intervention group alone is
pulmonary rehabilitation and does not meet our criteria of at least 2 components in the intervention group alone
Mazzoleni 2014 The study included 40 participants with a range of respiratory conditions, including 2 with bronchiectasis. We
contacted the study authors for data on the bronchiectasis participants alone but did not receive a reply
Newall 2005 Inspiratory muscle training plus pulmonary rehabilitation plus education versus pulmonary rehabilitation plus
education. Therefore, the only component in the intervention group alone is inspiratory muscle training and does
not meet our criteria of at least 2 components in the intervention group alone
Characteristics of ongoing studies [ordered by study ID]
NCT02179983
Trial name or title Tayside Rehabilitation in Bronchiectasis Exacerbations (TRIBE) : a randomized controlled trial (TRIBE)
Methods RCT of pulmonary rehabilitation after exacerbations of bronchiectasis
Participants Inclusion Criteria
1. Bronchiectasis confirmed on High Resolution CT scan
2. Clinical bronchiectasis confirmed by a respiratory physician. Documented exacerbation within the last
year
3. Independently mobile - i.e. able to undertake pulmonary rehabilitation
Exclusion Criteria
1. Inability to give informed consent to participate
2. Age < 18 years
3. Primary diagnosis of COPD
4. Significant comorbidity that would limit the ability to undertake pulmonary rehabilitation - i.e.
cerebrovascular, cardiovascular or musculoskeletal disease
5. CF
6. Aortic aneurysm
31Self-management for bronchiectasis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NCT02179983 (Continued)
7. Recent myocardial infarction (within previous year)or unstable angina
Interventions 1. No Intervention: standard care for exacerbation and follow-up without rehabilitation
2. Experimental: pulmonary rehabilitation (6 weeks of exercise and patient education after exacerbation)
Outcomes Primary Outcome Measures
1. 6 minute walk distance
Secondary Outcome Measures
1. Time to next exacerbation
2. Quality of life - St Georges respiratory questionnaire COPD assessment test
3. Pulmonary function tests (FEV1, FVC, FEF25-75)
4. Respiratory symptoms - patient diary cards
5. Sputum microbiology
6. 6 minute walk distance
Starting date June 2014
Contact information James D Chalmers, University of Dundee
Notes
CF: cystic fibrosis; COPD: chronic obstructive pulmonary disorder; CT: computed tomographic; RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Early rehab versus usual care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 SGRQ Total: mean difference 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 6 weeks 1 13 Mean Difference (IV, Fixed, 95% CI) -12.70 [-30.39, 4.
99]
1.2 3 months 1 12 Mean Difference (IV, Fixed, 95% CI) -9.15 [-28.08, 9.78]
1.3 12 months 1 7 Mean Difference (IV, Fixed, 95% CI) -10.27 [-45.15, 24.
61]
2 FEV1 L: mean difference 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 Discharge 1 17 Mean Difference (IV, Fixed, 95% CI) -0.13 [-0.60, 0.34]
2.2 6 weeks 1 14 Mean Difference (IV, Fixed, 95% CI) 0.07 [-0.55, 0.69]
2.3 3 months 1 13 Mean Difference (IV, Fixed, 95% CI) 0.15 [-0.55, 0.85]
2.4 12 months 1 8 Mean Difference (IV, Fixed, 95% CI) 0.30 [-1.11, 1.71]
3 Mortality 1 20 Odds Ratio (M-H, Fixed, 95% CI) 5.0 [0.64, 39.06]
Comparison 2. Expert patient programme versus usual care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 SGRQ Total: mean difference 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Post-intervention 1 62 Mean Difference (IV, Fixed, 95% CI) -6.5 [-16.59, 3.59]
1.2 3 months 1 60 Mean Difference (IV, Fixed, 95% CI) -2.60 [-12.97, 7.77]
1.3 6 months 1 60 Mean Difference (IV, Fixed, 95% CI) 3.20 [-6.64, 13.04]
2 Self-efficacy: Exercise 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 Postintervention 1 62 Mean Difference (IV, Fixed, 95% CI) 2.10 [0.89, 3.31]
2.2 3 months 1 60 Mean Difference (IV, Fixed, 95% CI) 1.40 [0.14, 2.66]
2.3 6 months 1 60 Mean Difference (IV, Fixed, 95% CI) 0.80 [-0.46, 2.06]
3 Self-efficacy: Disease info 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 Postintervention 1 62 Mean Difference (IV, Fixed, 95% CI) 1.5 [0.07, 2.93]
3.2 3 months 1 60 Mean Difference (IV, Fixed, 95% CI) 1.75 [0.38, 3.12]
3.3 6 months 1 60 Mean Difference (IV, Fixed, 95% CI) 1.30 [-0.13, 2.73]
4 Self-efficacy: Obtain help 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 Postintervention 1 62 Mean Difference (IV, Fixed, 95% CI) 1.10 [0.05, 2.15]
4.2 3 months 1 60 Mean Difference (IV, Fixed, 95% CI) 0.80 [-0.34, 1.94]
4.3 6 months 1 60 Mean Difference (IV, Fixed, 95% CI) 1.0 [-0.19, 2.19]
5 Self-efficacy: Communication 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.1 Postintervention 1 62 Mean Difference (IV, Fixed, 95% CI) 1.10 [0.14, 2.06]
5.2 3 months 1 60 Mean Difference (IV, Fixed, 95% CI) 0.90 [0.04, 1.76]
5.3 6 months 1 60 Mean Difference (IV, Fixed, 95% CI) 0.90 [-0.07, 1.87]
6 Self-efficacy: Manage disease 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
6.1 Postintervention 1 62 Mean Difference (IV, Fixed, 95% CI) 1.10 [0.17, 2.03]
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6.2 3 months 1 60 Mean Difference (IV, Fixed, 95% CI) 1.10 [0.27, 1.93]
6.3 6 months 1 60 Mean Difference (IV, Fixed, 95% CI) 0.70 [-0.27, 1.67]
7 Self-efficacy: Do chores 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
7.1 Postintervention 1 62 Mean Difference (IV, Fixed, 95% CI) 2.0 [0.78, 3.22]
7.2 3 months 1 60 Mean Difference (IV, Fixed, 95% CI) 1.20 [-0.14, 2.54]
7.3 6 months 1 60 Mean Difference (IV, Fixed, 95% CI) 1.20 [-0.01, 2.41]
8 Self-efficacy: Social activity 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
8.1 Postintervention 1 62 Mean Difference (IV, Fixed, 95% CI) 2.0 [0.84, 3.16]
8.2 3 months 1 60 Mean Difference (IV, Fixed, 95% CI) 0.90 [-0.42, 2.22]
8.3 6 months 1 60 Mean Difference (IV, Fixed, 95% CI) 0.40 [-0.88, 1.68]
9 Self-efficacy: Manage symptoms 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
9.1 Postintervention 1 62 Mean Difference (IV, Fixed, 95% CI) 1.90 [0.78, 3.02]
9.2 3 months 1 60 Mean Difference (IV, Fixed, 95% CI) 1.20 [0.13, 2.27]
9.3 6 months 1 60 Mean Difference (IV, Fixed, 95% CI) 0.70 [-0.41, 1.81]
10 Self-efficacy: Manage
breathlessness
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
10.1 Postintervention 1 62 Mean Difference (IV, Fixed, 95% CI) 1.5 [0.32, 2.68]
10.2 3 months 1 60 Mean Difference (IV, Fixed, 95% CI) 0.90 [-0.31, 2.11]
10.3 6 months 1 60 Mean Difference (IV, Fixed, 95% CI) 0.90 [-0.36, 2.16]
11 Self-efficacy: Manage
depression
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
11.1 Postintervention 1 62 Mean Difference (IV, Fixed, 95% CI) 2.0 [0.91, 3.09]
11.2 3 months 1 60 Mean Difference (IV, Fixed, 95% CI) 1.40 [0.19, 2.61]
11.3 6 months 1 60 Mean Difference (IV, Fixed, 95% CI) 1.30 [0.09, 2.51]
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Analysis 1.1. Comparison 1 Early rehab versus usual care, Outcome 1 SGRQ Total: mean difference.
Review: Self-management for bronchiectasis
Comparison: 1 Early rehab versus usual care
Outcome: 1 SGRQ Total: mean difference
Study or subgroup Early rehab Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 6 weeks
Greening 2014 5 51.98 (18.41) 8 64.68 (10.46) 100.0 % -12.70 [ -30.39, 4.99 ]
Subtotal (95% CI) 5 8 100.0 % -12.70 [ -30.39, 4.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
2 3 months
Greening 2014 4 57.48 (14.65) 8 66.63 (17.81) 100.0 % -9.15 [ -28.08, 9.78 ]
Subtotal (95% CI) 4 8 100.0 % -9.15 [ -28.08, 9.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
3 12 months
Greening 2014 3 45.75 (27.47) 4 56.02 (16.15) 100.0 % -10.27 [ -45.15, 24.61 ]
Subtotal (95% CI) 3 4 100.0 % -10.27 [ -45.15, 24.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
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Analysis 1.2. Comparison 1 Early rehab versus usual care, Outcome 2 FEV1 L: mean difference.
Review: Self-management for bronchiectasis
Comparison: 1 Early rehab versus usual care
Outcome: 2 FEV1 L: mean difference
Study or subgroup Early rehab Usual Care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Discharge
Greening 2014 8 0.88 (0.48) 9 1.01 (0.5) 100.0 % -0.13 [ -0.60, 0.34 ]
Subtotal (95% CI) 8 9 100.0 % -0.13 [ -0.60, 0.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
2 6 weeks
Greening 2014 5 1.08 (0.63) 9 1.01 (0.44) 100.0 % 0.07 [ -0.55, 0.69 ]
Subtotal (95% CI) 5 9 100.0 % 0.07 [ -0.55, 0.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.83)
3 3 months
Greening 2014 4 1.18 (0.64) 9 1.03 (0.47) 100.0 % 0.15 [ -0.55, 0.85 ]
Subtotal (95% CI) 4 9 100.0 % 0.15 [ -0.55, 0.85 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.67)
4 12 months
Greening 2014 3 1.33 (1.24) 5 1.03 (0.19) 100.0 % 0.30 [ -1.11, 1.71 ]
Subtotal (95% CI) 3 5 100.0 % 0.30 [ -1.11, 1.71 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.68)
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Analysis 1.3. Comparison 1 Early rehab versus usual care, Outcome 3 Mortality.
Review: Self-management for bronchiectasis
Comparison: 1 Early rehab versus usual care
Outcome: 3 Mortality
Study or subgroup Early rehab Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Greening 2014 4/8 2/12 100.0 % 5.00 [ 0.64, 39.06 ]
Total (95% CI) 8 12 100.0 % 5.00 [ 0.64, 39.06 ]
Total events: 4 (Early rehab), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.53 (P = 0.12)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
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Analysis 2.1. Comparison 2 Expert patient programme versus usual care, Outcome 1 SGRQ Total: mean
difference.
Review: Self-management for bronchiectasis
Comparison: 2 Expert patient programme versus usual care
Outcome: 1 SGRQ Total: mean difference
Study or subgroup Expert patient prog Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Post-intervention
Lavery 2011 31 45.3 (20.4337) 31 51.8 (20.0996) 100.0 % -6.50 [ -16.59, 3.59 ]
Subtotal (95% CI) 31 31 100.0 % -6.50 [ -16.59, 3.59 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
2 3 months
Lavery 2011 30 45.5 (20.6491) 30 48.1 (20.3205) 100.0 % -2.60 [ -12.97, 7.77 ]
Subtotal (95% CI) 30 30 100.0 % -2.60 [ -12.97, 7.77 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
3 6 months
Lavery 2011 30 47.9 (19.6085) 30 44.7 (19.2798) 100.0 % 3.20 [ -6.64, 13.04 ]
Subtotal (95% CI) 30 30 100.0 % 3.20 [ -6.64, 13.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
-50 -25 0 25 50
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Analysis 2.2. Comparison 2 Expert patient programme versus usual care, Outcome 2 Self-efficacy: Exercise.
Review: Self-management for bronchiectasis
Comparison: 2 Expert patient programme versus usual care
Outcome: 2 Self-efficacy: Exercise
Study or subgroup Expert patient prog Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Postintervention
Lavery 2011 31 7.1 (2.4498) 31 5 (2.3941) 100.0 % 2.10 [ 0.89, 3.31 ]
Subtotal (95% CI) 31 31 100.0 % 2.10 [ 0.89, 3.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.41 (P = 0.00064)
2 3 months
Lavery 2011 30 6.4 (2.5195) 30 5 (2.4648) 100.0 % 1.40 [ 0.14, 2.66 ]
Subtotal (95% CI) 30 30 100.0 % 1.40 [ 0.14, 2.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.18 (P = 0.030)
3 6 months
Lavery 2011 30 6.3 (2.5195) 30 5.5 (2.4648) 100.0 % 0.80 [ -0.46, 2.06 ]
Subtotal (95% CI) 30 30 100.0 % 0.80 [ -0.46, 2.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.24 (P = 0.21)
-4 -2 0 2 4
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Analysis 2.3. Comparison 2 Expert patient programme versus usual care, Outcome 3 Self-efficacy: Disease
info.
Review: Self-management for bronchiectasis
Comparison: 2 Expert patient programme versus usual care
Outcome: 3 Self-efficacy: Disease info
Study or subgroup Expert patient prog Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Postintervention
Lavery 2011 31 7.2 (2.8952) 31 5.7 (2.8396) 100.0 % 1.50 [ 0.07, 2.93 ]
Subtotal (95% CI) 31 31 100.0 % 1.50 [ 0.07, 2.93 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.06 (P = 0.039)
2 3 months
Lavery 2011 30 7.45 (2.7386) 30 5.7 (2.6838) 100.0 % 1.75 [ 0.38, 3.12 ]
Subtotal (95% CI) 30 30 100.0 % 1.75 [ 0.38, 3.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.50 (P = 0.012)
3 6 months
Lavery 2011 30 7.7 (2.8482) 30 6.4 (2.7934) 100.0 % 1.30 [ -0.13, 2.73 ]
Subtotal (95% CI) 30 30 100.0 % 1.30 [ -0.13, 2.73 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.78 (P = 0.074)
-4 -2 0 2 4
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Analysis 2.4. Comparison 2 Expert patient programme versus usual care, Outcome 4 Self-efficacy: Obtain
help.
Review: Self-management for bronchiectasis
Comparison: 2 Expert patient programme versus usual care
Outcome: 4 Self-efficacy: Obtain help
Study or subgroup Expert patient prog Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Postintervention
Lavery 2011 31 7.3 (2.1158) 31 6.2 (2.1158) 100.0 % 1.10 [ 0.05, 2.15 ]
Subtotal (95% CI) 31 31 100.0 % 1.10 [ 0.05, 2.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.05 (P = 0.041)
2 3 months
Lavery 2011 30 6.9 (2.2457) 30 6.1 (2.2457) 100.0 % 0.80 [ -0.34, 1.94 ]
Subtotal (95% CI) 30 30 100.0 % 0.80 [ -0.34, 1.94 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.38 (P = 0.17)
3 6 months
Lavery 2011 30 7.3 (2.3552) 30 6.3 (2.3552) 100.0 % 1.00 [ -0.19, 2.19 ]
Subtotal (95% CI) 30 30 100.0 % 1.00 [ -0.19, 2.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
-4 -2 0 2 4
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Analysis 2.5. Comparison 2 Expert patient programme versus usual care, Outcome 5 Self-efficacy:
Communication.
Review: Self-management for bronchiectasis
Comparison: 2 Expert patient programme versus usual care
Outcome: 5 Self-efficacy: Communication
Study or subgroup Expert patient prog Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Postintervention
Lavery 2011 31 8.9 (1.9487) 31 7.8 (1.893) 100.0 % 1.10 [ 0.14, 2.06 ]
Subtotal (95% CI) 31 31 100.0 % 1.10 [ 0.14, 2.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.25 (P = 0.024)
2 3 months
Lavery 2011 30 8.9 (1.6979) 30 8 (1.6979) 100.0 % 0.90 [ 0.04, 1.76 ]
Subtotal (95% CI) 30 30 100.0 % 0.90 [ 0.04, 1.76 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.05 (P = 0.040)
3 6 months
Lavery 2011 30 8.8 (1.917) 30 7.9 (1.917) 100.0 % 0.90 [ -0.07, 1.87 ]
Subtotal (95% CI) 30 30 100.0 % 0.90 [ -0.07, 1.87 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.82 (P = 0.069)
-4 -2 0 2 4
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Analysis 2.6. Comparison 2 Expert patient programme versus usual care, Outcome 6 Self-efficacy: Manage
disease.
Review: Self-management for bronchiectasis
Comparison: 2 Expert patient programme versus usual care
Outcome: 6 Self-efficacy: Manage disease
Study or subgroup Expert patient prog Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Postintervention
Lavery 2011 31 8 (1.893) 31 6.9 (1.8374) 100.0 % 1.10 [ 0.17, 2.03 ]
Subtotal (95% CI) 31 31 100.0 % 1.10 [ 0.17, 2.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.32 (P = 0.020)
2 3 months
Lavery 2011 30 7.9 (1.6432) 30 6.8 (1.6432) 100.0 % 1.10 [ 0.27, 1.93 ]
Subtotal (95% CI) 30 30 100.0 % 1.10 [ 0.27, 1.93 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.59 (P = 0.0095)
3 6 months
Lavery 2011 30 7.7 (1.917) 30 7 (1.917) 100.0 % 0.70 [ -0.27, 1.67 ]
Subtotal (95% CI) 30 30 100.0 % 0.70 [ -0.27, 1.67 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
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Analysis 2.7. Comparison 2 Expert patient programme versus usual care, Outcome 7 Self-efficacy: Do
chores.
Review: Self-management for bronchiectasis
Comparison: 2 Expert patient programme versus usual care
Outcome: 7 Self-efficacy: Do chores
Study or subgroup Expert patient prog Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Postintervention
Lavery 2011 31 7.5 (2.4498) 31 5.5 (2.4498) 100.0 % 2.00 [ 0.78, 3.22 ]
Subtotal (95% CI) 31 31 100.0 % 2.00 [ 0.78, 3.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.21 (P = 0.0013)
2 3 months
Lavery 2011 30 7.1 (2.6838) 30 5.9 (2.6291) 100.0 % 1.20 [ -0.14, 2.54 ]
Subtotal (95% CI) 30 30 100.0 % 1.20 [ -0.14, 2.54 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.75 (P = 0.080)
3 6 months
Lavery 2011 30 7.1 (2.41) 30 5.9 (2.3552) 100.0 % 1.20 [ -0.01, 2.41 ]
Subtotal (95% CI) 30 30 100.0 % 1.20 [ -0.01, 2.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.95 (P = 0.051)
-4 -2 0 2 4
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Analysis 2.8. Comparison 2 Expert patient programme versus usual care, Outcome 8 Self-efficacy: Social
activity.
Review: Self-management for bronchiectasis
Comparison: 2 Expert patient programme versus usual care
Outcome: 8 Self-efficacy: Social activity
Study or subgroup Expert patient prog Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Postintervention
Lavery 2011 31 7.7 (2.3385) 31 5.7 (2.3385) 100.0 % 2.00 [ 0.84, 3.16 ]
Subtotal (95% CI) 31 31 100.0 % 2.00 [ 0.84, 3.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.37 (P = 0.00076)
2 3 months
Lavery 2011 30 7 (2.6291) 30 6.1 (2.5743) 100.0 % 0.90 [ -0.42, 2.22 ]
Subtotal (95% CI) 30 30 100.0 % 0.90 [ -0.42, 2.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
3 6 months
Lavery 2011 30 6.7 (2.5195) 30 6.3 (2.5195) 100.0 % 0.40 [ -0.88, 1.68 ]
Subtotal (95% CI) 30 30 100.0 % 0.40 [ -0.88, 1.68 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
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Analysis 2.9. Comparison 2 Expert patient programme versus usual care, Outcome 9 Self-efficacy: Manage
symptoms.
Review: Self-management for bronchiectasis
Comparison: 2 Expert patient programme versus usual care
Outcome: 9 Self-efficacy: Manage symptoms
Study or subgroup Expert patient prog Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Postintervention
Lavery 2011 31 7 (2.2828) 31 5.1 (2.2271) 100.0 % 1.90 [ 0.78, 3.02 ]
Subtotal (95% CI) 31 31 100.0 % 1.90 [ 0.78, 3.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.32 (P = 0.00091)
2 3 months
Lavery 2011 30 6.6 (2.1361) 30 5.4 (2.0813) 100.0 % 1.20 [ 0.13, 2.27 ]
Subtotal (95% CI) 30 30 100.0 % 1.20 [ 0.13, 2.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.20 (P = 0.028)
3 6 months
Lavery 2011 30 6.3 (2.1909) 30 5.6 (2.1909) 100.0 % 0.70 [ -0.41, 1.81 ]
Subtotal (95% CI) 30 30 100.0 % 0.70 [ -0.41, 1.81 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.24 (P = 0.22)
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Analysis 2.10. Comparison 2 Expert patient programme versus usual care, Outcome 10 Self-efficacy:
Manage breathlessness.
Review: Self-management for bronchiectasis
Comparison: 2 Expert patient programme versus usual care
Outcome: 10 Self-efficacy: Manage breathlessness
Study or subgroup Expert patient prog Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Postintervention
Lavery 2011 31 6.5 (2.3941) 31 5 (2.3385) 100.0 % 1.50 [ 0.32, 2.68 ]
Subtotal (95% CI) 31 31 100.0 % 1.50 [ 0.32, 2.68 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.50 (P = 0.013)
2 3 months
Lavery 2011 30 6.1 (2.41) 30 5.2 (2.3552) 100.0 % 0.90 [ -0.31, 2.11 ]
Subtotal (95% CI) 30 30 100.0 % 0.90 [ -0.31, 2.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.46 (P = 0.14)
3 6 months
Lavery 2011 30 6.1 (2.5195) 30 5.2 (2.4648) 100.0 % 0.90 [ -0.36, 2.16 ]
Subtotal (95% CI) 30 30 100.0 % 0.90 [ -0.36, 2.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
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Analysis 2.11. Comparison 2 Expert patient programme versus usual care, Outcome 11 Self-efficacy:
Manage depression.
Review: Self-management for bronchiectasis
Comparison: 2 Expert patient programme versus usual care
Outcome: 11 Self-efficacy: Manage depression
Study or subgroup Expert patient prog Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Postintervention
Lavery 2011 31 7.7 (2.2271) 31 5.7 (2.1714) 100.0 % 2.00 [ 0.91, 3.09 ]
Subtotal (95% CI) 31 31 100.0 % 2.00 [ 0.91, 3.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.58 (P = 0.00034)
2 3 months
Lavery 2011 30 7.3 (2.41) 30 5.9 (2.3552) 100.0 % 1.40 [ 0.19, 2.61 ]
Subtotal (95% CI) 30 30 100.0 % 1.40 [ 0.19, 2.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.28 (P = 0.023)
3 6 months
Lavery 2011 30 7.3 (2.41) 30 6 (2.3552) 100.0 % 1.30 [ 0.09, 2.51 ]
Subtotal (95% CI) 30 30 100.0 % 1.30 [ 0.09, 2.51 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.11 (P = 0.035)
-4 -2 0 2 4
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A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group’s Specialised Register
(CAGR)
Electronic searches: core databases
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Database Frequency of search
MEDLINE (Ovid) Weekly
Embase (Ovid) Weekly
CENTRAL (crso.cochrane.org) Monthly
PsycINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify trials for the CAGR
Bronchiectasis topic search
1. exp Bronchiectasis/
2. bronchiect$.mp.
3. bronchoect$.mp.
4. kartagener$.mp.
5. (bronchial$ adj3 dilat$).mp.
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6. or/1-5
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter (Lefebvre 2011) are adapted to identify trials in other electronic databases.
Appendix 2. Search strategy to identify relevant trials from the CAGR
#1 BRONCH:MISC1
#2 MeSH DESCRIPTOR Bronchiectasis Explode All
#3 bronchiect*
#4 #1 or #2 or #3
#5 MeSH DESCRIPTOR Self Care Explode All
#6 MeSH DESCRIPTOR Education
#7 MeSH DESCRIPTOR Patient Education as Topic
#8 educat*
#9 self-manag*
#10 “self manag*”
#11 self-car* or “self car*”
#12 train* or instruct*
#13 “patient cent*” or patient-cent*
#14 patient-focus* or “patient focus*”
#15 patient-education or “patient education”
#16 “management plan” or management-plan
#17 management* NEAR1 program*
#18 behavior* or behaviour*
#19 disease* NEAR2 management*
#20 self-efficac*
#21 empower*
#22 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21
#23 #4 AND #22
[In search line #1, MISC1 denotes the field in the record where the reference has been coded for condition, in this case, bronchiectasis]
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